Term
|
Definition
| apnea from succinylcholine |
|
|
Term
| Lack NADH-methemoglobin reductase |
|
Definition
| Blue-skin when taking nitrites, sulfonamides, primiquin |
|
|
Term
| Low liver acetyl transferase |
|
Definition
| Increased Isoniazid toxicity |
|
|
Term
|
Definition
| Hemolytic anemia from primaquine and others |
|
|
Term
| Low porphyrin synthesis enzymes |
|
Definition
| Hepatic Porphyria from barbiturates, estrogens, sulfonamides, chloroquine |
|
|
Term
| Tetracycline interacts with? |
|
Definition
| It will bind calcium and prevent absorption |
|
|
Term
| Sequinodir should be taken with? |
|
Definition
| This should be taken with food, otherwise you don't absorb |
|
|
Term
| FDA Pregnancy Risk Categories |
|
Definition
| A=remote risk to fetus; B=slight risk to fetus; C=some risk to fetus; D=proven risk to fetus but benefits may outweigh risk; X=proven risk to fetus with risk outweighing benefits |
|
|
Term
|
Definition
| Used to prevent spontaneous abortion, but daughters got vaginal/uterine cancers |
|
|
Term
| Neonate Pharmacokinetic differences |
|
Definition
| A=+/-; D=low albumin mean higher free levels, BBB not well formed; M=low; E=low |
|
|
Term
| Children Pharmacokinetic differences |
|
Definition
| Metabolize much faster, peaks at age 2 |
|
|
Term
| Child dosage determination |
|
Definition
| (SA_child*Dose_adult) / (1.73m^2) |
|
|
Term
| Geriatric Pharmacokinetics |
|
Definition
| A=~=; D=reduced in serum, decrease water, more fat; M=+/-; E=reduced |
|
|
Term
| Geriatric Pharmacodynamics |
|
Definition
| β-blockers less, oral anticoagulants more effective |
|
|
Term
| Pregnants Pharmacokinetic differences |
|
Definition
| A=-; D=increased especially lipophillic; M=increased; E=increased |
|
|
Term
|
Definition
| switching the drug originally prescribed with a drug from the same class that has the same mechanism of action |
|
|
Term
|
Definition
| switching the drug originally prescribed with a completely different type of drug from a different drug group with different mechanism of action |
|
|
Term
|
Definition
| high abuse potential, no accepted medical use, severe dependence |
|
|
Term
|
Definition
| least abuse of all controlled, accepted medical use, limited dependence liability |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| Anabolic steroid (S. III) |
|
|
Term
|
Definition
|
|
Term
|
Definition
| Pure Food and Drug Act - drugs must be pure - The Jungle |
|
|
Term
|
Definition
| Food, Drug, and Cosmetic Act - drug must be safe - elixer of sulfonilamide |
|
|
Term
|
Definition
| Durham Humphrey - drug classes label/off-label |
|
|
Term
|
Definition
| Kefauver-Harris - proof of effectiveness |
|
|
Term
|
Definition
| Comprehensive Drug Abuse Prev/Control Act - schedules of drug |
|
|
Term
|
Definition
| Drug price compeitition and patent act - extend innovator drug patetnts |
|
|
Term
|
Definition
| Dietary supplement health and education act |
|
|
